If CD16 got the greenlight in ~2 weeks, the same should apply to the "new CD16" and CD17... rather they hone in on cohort and endpoints (the FDA suggesting "alive and free of respiratory failure" is highly encouraging). Way better to do this at the beginning than waste time at 75% trying to redesign the study, imo.